(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Xeris Biopharma Holdings's revenue in 2026 is $335,414,000.On average, 9 Wall Street analysts forecast XERS's revenue for 2026 to be $71,639,117,837, with the lowest XERS revenue forecast at $68,092,987,885, and the highest XERS revenue forecast at $74,565,358,748. On average, 9 Wall Street analysts forecast XERS's revenue for 2027 to be $87,758,056,090, with the lowest XERS revenue forecast at $80,618,392,907, and the highest XERS revenue forecast at $94,569,542,722.
In 2028, XERS is forecast to generate $101,184,123,424 in revenue, with the lowest revenue forecast at $92,946,891,999 and the highest revenue forecast at $109,310,139,462.